June 10, 2019
MSD’s anti-PD-1 antibody Keytruda (pembrolizumab) notched up the crown of the best-selling drug in Japan in May with 9.8 billion yen on an NHI price basis, according to a monthly snapshot report released by market research firm Encise. Chugai Pharmaceutical’s...read more